Antineoplastics
1
Reactions 1424 - 20 Oct 2012 Antineoplastics Acneiform eruptions and other skin toxicities: 23 case reports In a retrospective study, 17 men and six women aged 26–86 years developed acneiform eruptions and other skin toxicities during chemotherapy, including with erlotinib, cetuximab, everolimus, pemetrexed, irinotecan and bevacizumab. Eleven patients were receiving erlotinib for lung cancer or lymphocytic thyoma (two in combination with bevacizumab or pemetrexed), 10 patients received cetuximab for colon, rectal or stomach cancer (one in combination with bevacizumab), one patient received irinotecan and bevacizumab for colon cancer and one patient received everolimus for kidney cancer [routes and dosages not stated]. Acneiform eruptions involved the face in all patients, as well as the trunk, hairy skin, neck and extremities in some patients. Lesions developed within 2 weeks of starting chemotherapy in all cases. Pustular lesions were observed in 17 patients, with three of these patients also developing early-stage furuncle-like nodular lesions. Seven patients experienced paronychia, with hypertrophic granulation tissue in one instance. Two patients had fissures on their finger tips, and eight patients developed xerosis on their trunk or extremities. In one patient, pyogenic granuloma-like hypertrophic granulation tissue was observed over an abdominal operation scar. Aphthous mouth ulcers were also present in once case. Trichomegaly developed during the third month or at 6 months of treatment in 2 patients. Fifteen patients received antibacterial therapy with or without topical medications, while five patients received topical treatment alone. None of the patients were advised to discontinue chemotherapy. Follow-up data was available for 10 patients, of which eight responded well to treatment [outcomes for remaining patients not stated]. Author comment: The best known cause of acneiform eruptions related to chemotherapeutic medications are the EGFR inhibitors. Yazganoglu KD, et al. Acneiform eruption and other dermatologic side effects induced by targeted cancer therapy: A retrospective analysis. Deri Hastaliklari ve Frengi Arsivi 46: 84-89, No. 2, 2012. Available from: URL: http:// dx.doi.org/10.4274/Turkderm.47640 [Turkish; summarised from a translation] - Turkey 803078405 1 Reactions 20 Oct 2012 No. 1424 0114-9954/10/1424-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Antineoplastics
Reactions 1424 - 20 Oct 2012
Antineoplastics
Acneiform eruptions and other skin toxicities:23 case reports
In a retrospective study, 17 men and six women aged26–86 years developed acneiform eruptions and other skintoxicities during chemotherapy, including with erlotinib,cetuximab, everolimus, pemetrexed, irinotecan andbevacizumab.
Eleven patients were receiving erlotinib for lung canceror lymphocytic thyoma (two in combination withbevacizumab or pemetrexed), 10 patients receivedcetuximab for colon, rectal or stomach cancer (one incombination with bevacizumab), one patient receivedirinotecan and bevacizumab for colon cancer and onepatient received everolimus for kidney cancer [routes anddosages not stated]. Acneiform eruptions involved the facein all patients, as well as the trunk, hairy skin, neck andextremities in some patients. Lesions developed within2 weeks of starting chemotherapy in all cases. Pustularlesions were observed in 17 patients, with three of thesepatients also developing early-stage furuncle-like nodularlesions. Seven patients experienced paronychia, withhypertrophic granulation tissue in one instance. Twopatients had fissures on their finger tips, and eight patientsdeveloped xerosis on their trunk or extremities. In onepatient, pyogenic granuloma-like hypertrophic granulationtissue was observed over an abdominal operation scar.Aphthous mouth ulcers were also present in once case.Trichomegaly developed during the third month or at6 months of treatment in 2 patients.
Fifteen patients received antibacterial therapy with orwithout topical medications, while five patients receivedtopical treatment alone. None of the patients were advisedto discontinue chemotherapy. Follow-up data was availablefor 10 patients, of which eight responded well to treatment[outcomes for remaining patients not stated].
Author comment: The best known cause of acneiformeruptions related to chemotherapeutic medications are theEGFR inhibitors.Yazganoglu KD, et al. Acneiform eruption and other dermatologic side effectsinduced by targeted cancer therapy: A retrospective analysis. Deri Hastaliklari veFrengi Arsivi 46: 84-89, No. 2, 2012. Available from: URL: http://dx.doi.org/10.4274/Turkderm.47640 [Turkish; summarised from a translation] -Turkey 803078405
1
Reactions 20 Oct 2012 No. 14240114-9954/10/1424-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
